Key facts
- Protego Biopharma’s last known valuation is $216.5M (Mar 2025).
- It has raised $182.1M across 3 recorded rounds; the latest was Early Stage VC ($32.9M) in Oct 2025.
- Notable investors include Lightspeed Venture Partners, Johnson & Johnson Innovation - JLABS, Digitalis Ventures, Forbion, Novartis Venture Fund — 12 tracked in total.
- Protego Biopharma has filed 3 Form Ds with the SEC since 2019, most recently Dec 2025 ($32.9M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Protego Biopharma
Funding rounds
3 roundsAbout Protego Biopharma
Developer of a small molecule therapeutics platform designed to reprogram protein folding for the treatment of various systemic amyloid diseases and protein misfolding diseases. The company's drug discovery platform in order to address the protein misfolding problem, modulates the energetics of proteins using pharmacological chaperones and/or modulates the cellular folding, secretory and stress pathways, enabling doctors to obtain disease-modifying therapeutics.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2011
- Employees
- 22
- Website
- protegobio.com/
- Ownership
- Privately Held (backing)
Protego Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Protego Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Protego Biopharma in its N-PORT filings yet. We sweep new filings monthly.